secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001493152-26-018018
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition
--------------------------------------------------------------------------------

- Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.
- Commitment letter for up to $22.5M senior secured credit facility to fund proposed $30M cash acquisition of DCS.
- DCS (automotive supplier) had $200M+ revenue and $20M+ adjusted EBITDA in FY2025 (unaudited).
- Stockholders' equity now exceeds $2.5M Nasdaq minimum; no new equity anticipated to consummate DCS purchase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226018018/0001493152-26-018018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315226018018/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-018018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer